← all drugs
Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection
being discontinued · Anti-Infective · Snapshot: 2026-10-09
- Manufacturers listed
- Merck Sharp & Dohme LLC
- Machine-readable
- JSON for this drug
Presentations (1)
| Presentation | Company | Availability | Updated |
|---|---|---|---|
| RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02) | Merck Sharp & Dohme LLC | unknown | 09/09/2026 |
History
Daily tracking of this drug began 2026-09-10.
- 2026-09-10 — Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection appeared on the FDA shortage list (being discontinued)
Each daily snapshot is compared with the one before it; status changes, availability-wording revisions, and arrivals or removals are listed here. A change the FDA makes and reverses between two snapshots is not seen. Every daily record is kept in the public repository.
Not medical advice. ShortSupply republishes the FDA's drug-shortage data with history added. Talk to your pharmacist or prescriber about your situation — never change medication based on this site.